About Us > Ilana Schlam, MD, MPH

Ilana Schlam, MD, MPH

Breast Medical Oncologist, Clinical Researcher, Dana-Farber Cancer Institute

Ilana Schlam, MD, MPH

Highlights

  • Research focuses on drug development and identifying biomarkers of response to novel therapies
featured_paragraph

Ilana Schlam, MD, MPH, is a breast medical oncologist and clinical researcher at Dana-Farber Cancer Institute and associate director of the Early Breast Cancer Program (LEAP). Her research focuses on drug development and identifying biomarkers of response to novel therapies.

contributions_carousel

Contributions

Sacituzumab govitecan

10/12/25 | BY: Ilana Schlam

Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate, a treatment that pairs a chemotherapy medicine with a targeted therapy. It is approved to treat people diagnosed with several types of metastatic breast cancer.

Read More
 | 3 Min. Read

Ado-trastuzumab emtansine

10/12/25 | BY: Ilana Schlam

Ado-trastuzumab emtansine (Kadcyla or T-DM1) combines the targeted therapy trastuzumab (Herceptin) with the chemotherapy medicine emtansine to treat HER2-positive breast cancer.

Read More
 | 3 Min. Read

Trastuzumab deruxtecan

10/12/25 | BY: Ilana Schlam

Trastuzumab deruxtecan (Enhertu or T-DXd) is an antibody-drug conjugate that treats HER2-positive, HER2-low, or HER2-ultralow breast cancer that cannot be removed surgically or that has spread to another part of the body.

Read More
 | 6 Min. Read